181 related articles for article (PubMed ID: 21737503)
21. Quantification of excision repair cross-complementing group 1 and survival in p16-negative squamous cell head and neck cancers.
Mehra R; Zhu F; Yang DH; Cai KQ; Weaver J; Singh MK; Nikonova AS; Golemis EA; Flieder DB; Cooper HS; Lango M; Ridge JA; Burtness B
Clin Cancer Res; 2013 Dec; 19(23):6633-43. PubMed ID: 24088734
[TBL] [Abstract][Full Text] [Related]
22. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial.
Fakhry C; Westra WH; Li S; Cmelak A; Ridge JA; Pinto H; Forastiere A; Gillison ML
J Natl Cancer Inst; 2008 Feb; 100(4):261-9. PubMed ID: 18270337
[TBL] [Abstract][Full Text] [Related]
23. Afatinib versus placebo as adjuvant therapy after chemoradiation in a double-blind, phase III study (LUX-Head & Neck 2) in patients with primary unresected, clinically intermediate-to-high-risk head and neck cancer: study protocol for a randomized controlled trial.
Burtness B; Bourhis JP; Vermorken JB; Harrington KJ; Cohen EE
Trials; 2014 Nov; 15():469. PubMed ID: 25432788
[TBL] [Abstract][Full Text] [Related]
24. Randomized trial comparing surgery and adjuvant radiotherapy versus concurrent chemoradiotherapy in patients with advanced, nonmetastatic squamous cell carcinoma of the head and neck: 10-year update and subset analysis.
Iyer NG; Tan DS; Tan VK; Wang W; Hwang J; Tan NC; Sivanandan R; Tan HK; Lim WT; Ang MK; Wee J; Soo KC; Tan EH
Cancer; 2015 May; 121(10):1599-607. PubMed ID: 25639864
[TBL] [Abstract][Full Text] [Related]
25. MiR-21 as prognostic biomarker in head and neck squamous cell carcinoma patients undergoing an organ preservation protocol.
Arantes LM; Laus AC; Melendez ME; de Carvalho AC; Sorroche BP; De Marchi PR; Evangelista AF; Scapulatempo-Neto C; de Souza Viana L; Carvalho AL
Oncotarget; 2017 Feb; 8(6):9911-9921. PubMed ID: 28039483
[TBL] [Abstract][Full Text] [Related]
26. Potentially novel candidate biomarkers for head and neck squamous cell carcinoma identified using an integrated cell line-based discovery strategy.
Sepiashvili L; Hui A; Ignatchenko V; Shi W; Su S; Xu W; Huang SH; O'Sullivan B; Waldron J; Irish JC; Perez-Ordonez B; Liu FF; Kislinger T
Mol Cell Proteomics; 2012 Nov; 11(11):1404-15. PubMed ID: 22918226
[TBL] [Abstract][Full Text] [Related]
27. Regional control after concomitant chemoradiotherapy without planned neck dissection in node-positive head and neck squamous cell carcinomas.
Sakashita T; Homma A; Oridate N; Suzuki S; Hatakeyama H; Kano S; Mizumachi T; Onimaru R; Tsuchiya K; Yasuda K; Shirato H; Fukuda S
Auris Nasus Larynx; 2013 Apr; 40(2):211-5. PubMed ID: 22867524
[TBL] [Abstract][Full Text] [Related]
28. The expression of activin receptor-like kinase 1 among patients with head and neck cancer.
Chien CY; Chuang HC; Chen CH; Fang FM; Chen WC; Huang CC; Huang HY
Otolaryngol Head Neck Surg; 2013 Jun; 148(6):965-73. PubMed ID: 23447486
[TBL] [Abstract][Full Text] [Related]
29. ERCC1, XPF and XPA-locoregional differences and prognostic value of DNA repair protein expression in patients with head and neck squamous cell carcinoma.
Prochnow S; Wilczak W; Bosch V; Clauditz TS; Muenscher A
Clin Oral Investig; 2019 Aug; 23(8):3319-3329. PubMed ID: 30498981
[TBL] [Abstract][Full Text] [Related]
30. GSTP1 c.313A>G, XPD c.934G>A, XPF c.2505T>C and CASP9 c.-1339A>G Polymorphisms and Severity of Vomiting in Head and Neck Cancer Patients treated with Cisplatin Chemoradiation.
Carron J; Lopes-Aguiar L; Costa EFD; Nogueira GAS; Lima TRP; Pincinato EC; Visacri MB; Quintanilha JCF; Moriel P; Lourenço GJ; Lima CSP
Basic Clin Pharmacol Toxicol; 2017 Dec; 121(6):520-525. PubMed ID: 28686330
[TBL] [Abstract][Full Text] [Related]
31. Growth inhibition and chemo-radiosensitization of head and neck squamous cell carcinoma (HNSCC) by survivin-siRNA lentivirus.
Khan Z; Khan AA; Prasad GB; Khan N; Tiwari RP; Bisen PS
Radiother Oncol; 2016 Feb; 118(2):359-68. PubMed ID: 26747757
[TBL] [Abstract][Full Text] [Related]
32. The prognostic and predictive value of excision repair cross-complementation group 1 (ERCC1) protein in 1288 patients with head and neck squamous cell carcinoma treated with platinum-based therapy: a meta-analysis.
Bišof V; Zajc Petranović M; Rakušić Z; Samardžić KR; Juretić A
Eur Arch Otorhinolaryngol; 2016 Sep; 273(9):2305-17. PubMed ID: 26179868
[TBL] [Abstract][Full Text] [Related]
33. Phase III randomized trial of preoperative concurrent chemoradiotherapy versus preoperative radiotherapy for patients with locally advanced head and neck squamous cell carcinoma.
Yi J; Huang X; Xu Z; Liu S; Wang X; He X; Luo D; Luo J; Xiao J; Zhang S; Wang K; Qu Y; Tang Y; Liu W; Xu G; Gao L; Wang D
Oncotarget; 2017 Jul; 8(27):44842-44850. PubMed ID: 28179586
[TBL] [Abstract][Full Text] [Related]
34. CCND1 as a predictive biomarker of neoadjuvant chemotherapy in patients with locally advanced head and neck squamous cell carcinoma.
Feng Z; Guo W; Zhang C; Xu Q; Zhang P; Sun J; Zhu H; Wang Z; Li J; Wang L; Wang B; Ren G; Ji T; Tu W; Yang X; Qiu W; Mao L; Zhang Z; Chen W
PLoS One; 2011; 6(10):e26399. PubMed ID: 22065993
[TBL] [Abstract][Full Text] [Related]
35. Ku70 predicts response and primary tumor recurrence after therapy in locally advanced head and neck cancer.
Pavón MA; Parreño M; León X; Sancho FJ; Céspedes MV; Casanova I; Lopez-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
Int J Cancer; 2008 Sep; 123(5):1068-79. PubMed ID: 18546291
[TBL] [Abstract][Full Text] [Related]
36. Synergistic antitumor effect of AAV-mediated TRAIL expression combined with cisplatin on head and neck squamous cell carcinoma.
Jiang M; Liu Z; Xiang Y; Ma H; Liu S; Liu Y; Zheng D
BMC Cancer; 2011 Feb; 11():54. PubMed ID: 21291526
[TBL] [Abstract][Full Text] [Related]
37. Inferior outcomes in immunosuppressed patients with high-risk cutaneous squamous cell carcinoma of the head and neck treated with surgery and radiation therapy.
Manyam BV; Gastman B; Zhang AY; Reddy CA; Burkey BB; Scharpf J; Alam DS; Fritz MA; Vidimos AT; Koyfman SA
J Am Acad Dermatol; 2015 Aug; 73(2):221-7. PubMed ID: 26028524
[TBL] [Abstract][Full Text] [Related]
38. S-Nitrosoglutathione-mediated STAT3 regulation in efficacy of radiotherapy and cisplatin therapy in head and neck squamous cell carcinoma.
Kaliyaperumal K; Sharma AK; McDonald DG; Dhindsa JS; Yount C; Singh AK; Won JS; Singh I
Redox Biol; 2015 Dec; 6():41-50. PubMed ID: 26177470
[TBL] [Abstract][Full Text] [Related]
39. Anterior gradient protein 2 expression in high grade head and neck squamous cell carcinoma correlated with cancer stem cell and epithelial mesenchymal transition.
Ma SR; Wang WM; Huang CF; Zhang WF; Sun ZJ
Oncotarget; 2015 Apr; 6(11):8807-21. PubMed ID: 25871396
[TBL] [Abstract][Full Text] [Related]
40. Functional organ preservation after chemoradiotherapy in elderly patients with loco-regionally advanced head and neck squamous cell carcinoma.
Boscolo-Rizzo P; Muzzi E; Trabalzini F; Gava A; Stellin M; Da Mosto MC
Eur Arch Otorhinolaryngol; 2011 Sep; 268(9):1349-55. PubMed ID: 21258812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
